These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
347 related articles for article (PubMed ID: 19695406)
1. Nilotinib for imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase, accelerated phase, or blast crisis: a single- and multiple-dose, open-label pharmacokinetic study in Chinese patients. Zhou L; Meng F; Yin O; Wang J; Wang Y; Wei Y; Hu P; Shen Z Clin Ther; 2009 Jul; 31(7):1568-75. PubMed ID: 19695406 [TBL] [Abstract][Full Text] [Related]
2. Expanding Nilotinib Access in Clinical Trials (ENACT), an open-label multicenter study of oral nilotinib in adult patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase or blast crisis. Nicolini FE; Masszi T; Shen Z; Gallagher NJ; Jootar S; Powell BL; Dorlhiac-Llacer PE; Zheng M; Szczudlo T; Turkina A Leuk Lymphoma; 2012 May; 53(5):907-14. PubMed ID: 22023530 [TBL] [Abstract][Full Text] [Related]
3. Nilotinib population pharmacokinetics and exposure-response analysis in patients with imatinib-resistant or -intolerant chronic myeloid leukemia. Giles FJ; Yin OQ; Sallas WM; le Coutre PD; Woodman RC; Ottmann OG; Baccarani M; Kantarjian HM Eur J Clin Pharmacol; 2013 Apr; 69(4):813-23. PubMed ID: 23052406 [TBL] [Abstract][Full Text] [Related]
4. Dasatinib and nilotinib for imatinib-resistant or -intolerant chronic myeloid leukaemia: a systematic review and economic evaluation. Rogers G; Hoyle M; Thompson Coon J; Moxham T; Liu Z; Pitt M; Stein K Health Technol Assess; 2012; 16(22):1-410. PubMed ID: 22551803 [TBL] [Abstract][Full Text] [Related]
5. Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib. Cortes JE; Hochhaus A; le Coutre PD; Rosti G; Pinilla-Ibarz J; Jabbour E; Gillis K; Woodman RC; Blakesley RE; Giles FJ; Kantarjian HM; Baccarani M Blood; 2011 May; 117(21):5600-6. PubMed ID: 21467546 [TBL] [Abstract][Full Text] [Related]
6. Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia. Deremer DL; Ustun C; Natarajan K Clin Ther; 2008 Nov; 30(11):1956-75. PubMed ID: 19108785 [TBL] [Abstract][Full Text] [Related]
7. Effects of hepatic impairment on the pharmacokinetics of nilotinib: an open-label, single-dose, parallel-group study. Yin OQ; Gallagher N; Tanaka C; Fisher D; Sethuraman V; Zhou W; Lin TH; Heuman D; Schran H Clin Ther; 2009; 31 Pt 2():2459-69. PubMed ID: 20110053 [TBL] [Abstract][Full Text] [Related]
8. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. Saglio G; Kim DW; Issaragrisil S; le Coutre P; Etienne G; Lobo C; Pasquini R; Clark RE; Hochhaus A; Hughes TP; Gallagher N; Hoenekopp A; Dong M; Haque A; Larson RA; Kantarjian HM; N Engl J Med; 2010 Jun; 362(24):2251-9. PubMed ID: 20525993 [TBL] [Abstract][Full Text] [Related]
9. Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results. le Coutre PD; Giles FJ; Hochhaus A; Apperley JF; Ossenkoppele GJ; Blakesley R; Shou Y; Gallagher NJ; Baccarani M; Cortes J; Kantarjian HM Leukemia; 2012 Jun; 26(6):1189-94. PubMed ID: 22076466 [TBL] [Abstract][Full Text] [Related]
10. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Kantarjian HM; Hochhaus A; Saglio G; De Souza C; Flinn IW; Stenke L; Goh YT; Rosti G; Nakamae H; Gallagher NJ; Hoenekopp A; Blakesley RE; Larson RA; Hughes TP Lancet Oncol; 2011 Sep; 12(9):841-51. PubMed ID: 21856226 [TBL] [Abstract][Full Text] [Related]
11. Expanding Nilotinib Access in Clinical Trials (ENACT): an open-label, multicenter study of oral nilotinib in adult patients with imatinib-resistant or imatinib-intolerant Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase. Nicolini FE; Turkina A; Shen ZX; Gallagher N; Jootar S; Powell BL; De Souza C; Zheng M; Szczudlo T; le Coutre P Cancer; 2012 Jan; 118(1):118-26. PubMed ID: 21732337 [TBL] [Abstract][Full Text] [Related]
12. Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy. Giles FJ; Abruzzese E; Rosti G; Kim DW; Bhatia R; Bosly A; Goldberg S; Kam GL; Jagasia M; Mendrek W; Fischer T; Facon T; Dünzinger U; Marin D; Mueller MC; Shou Y; Gallagher NJ; Larson RA; Mahon FX; Baccarani M; Cortes J; Kantarjian HM Leukemia; 2010 Jul; 24(7):1299-301. PubMed ID: 20520639 [TBL] [Abstract][Full Text] [Related]
13. Tasigna for chronic and accelerated phase Philadelphia chromosome--positive chronic myelogenous leukemia resistant to or intolerant of imatinib. Hazarika M; Jiang X; Liu Q; Lee SL; Ramchandani R; Garnett C; Orr MS; Sridhara R; Booth B; Leighton JK; Timmer W; Harapanhalli R; Dagher R; Justice R; Pazdur R Clin Cancer Res; 2008 Sep; 14(17):5325-31. PubMed ID: 18765523 [TBL] [Abstract][Full Text] [Related]
14. Tolerability and pharmacokinetics of ranolazine following single and multiple sustained-release doses in Chinese healthy adult volunteers: a randomized, open-label, Latin square design, phase I study. Tan QY; Li HD; Zhu RH; Zhang QZ; Zhang J; Peng WX Am J Cardiovasc Drugs; 2013 Feb; 13(1):17-25. PubMed ID: 23355361 [TBL] [Abstract][Full Text] [Related]
15. A Phase I/II study of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL. Tojo A; Usuki K; Urabe A; Maeda Y; Kobayashi Y; Jinnai I; Ohyashiki K; Nishimura M; Kawaguchi T; Tanaka H; Miyamura K; Miyazaki Y; Hughes T; Branford S; Okamoto S; Ishikawa J; Okada M; Usui N; Tanii H; Amagasaki T; Natori H; Naoe T Int J Hematol; 2009 Jun; 89(5):679-88. PubMed ID: 19449194 [TBL] [Abstract][Full Text] [Related]